# Chronic Performance Assessment

Design and execute chronic in-vivo studies to characterize long-term implant performance including signal quality degradation, tissue response, and failure modes.

## Inputs

- `encapsulation-design`: Encapsulation system with expected lifetime
- `sterilization-protocol`: Validated sterilization method
- `electrode-design`: Electrode array specification

## Outputs

- `chronic-performance-data`: Signal quality (SNR, unit yield) over time, impedance tracking, tissue histology at explant, failure mode analysis
- `implant-lifetime-assessment`: Estimated functional lifetime with confidence interval, identified failure modes and their timelines, design improvements for next iteration

## Process

1. Design the chronic study. For intracortical arrays, a minimum 6-month implant duration demonstrates chronic stability (12 months preferred for regulatory submissions). Species selection: non-human primate for closest brain analogy, rodent for larger cohorts at lower cost. Sample size: minimum 6 animals per group for statistical power on histological endpoints. Define recording schedule: daily for first week, weekly for first month, monthly thereafter. Track electrode impedance at 1 kHz, signal amplitude (peak-to-peak of detected spikes), noise floor (RMS of signal with no detected spikes), unit yield (channels with detectable single units / total channels).
2. Characterize the foreign body response timeline. Week 1: acute inflammation (activated microglia, edema, albumin leakage from blood-brain barrier disruption). Week 2-4: chronic inflammation onset (reactive astrocytes begin forming glial sheath, macrophage recruitment). Month 1-3: glial scar matures (dense astrocyte sheath 50-200 um thick around implant, neuronal die-back within 50-100 um of electrode surface). Month 3+: stable chronic state. Quantify by immunohistochemistry at explant: GFAP (astrocytes), Iba-1 (microglia), NeuN (neurons) at 50, 100, 200, 500 um from electrode track.
3. Track signal quality degradation. Typical trajectory for rigid silicon arrays: 50-80% of channels record single units at week 1, declining to 20-40% by month 6 due to glial encapsulation increasing electrode-to-neuron distance. Impedance typically increases 2-5x over 6 months as tissue encapsulates. Flexible arrays show slower degradation (hypothesis: reduced micromotion-driven inflammation). Plot unit yield and mean SNR vs time with 95% confidence intervals.
4. Identify and classify failure modes. Electrical: broken traces (from chronic flexion), connector failure, encapsulation breach (moisture ingress causing corrosion or short circuits). Biological: glial encapsulation (gradual signal loss), infection (acute, usually from surgical contamination), foreign body reaction to specific materials. Mechanical: implant migration, cable breakage at strain point. For each failure mode, record time-to-failure and build a reliability model (Weibull distribution). Use this data to define the implant's usable lifetime and prioritize design improvements.

---

Copyright 2024-present The Wayfinder Trust. All rights reserved.
